A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S.

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Novo Nordisk on Monday lowered the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment Ozempic in a challenge to Eli Lilly’s Zepbound after President Donald Trump announced ...

Eli Lilly has lowered the price of its GLP-1 drug Zepbound (tirzepatide) in single-dose vials, with the starting dose now available for $299 per month through the company’s direct-to-consumer platform ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...